Expression Data from transNOAH breast cancer trial
Ontology highlight
ABSTRACT: These data can be used for evaluation of the clinical utility of the research-based PAM50 subtype predictor in predicting pathological complete response (pCR) and event-free survival (EFS) in women enrolled in the NeOAdjuvant Herceptin (NOAH) trial. The NeOAdjuvant Herceptin [NOAH] trial demonstrated that trastuzumab significantly improves pCR rates and 3-year event-free survival (EFS) in combination with neoadjuvant chemotherapy compared with neoadjuvant chemotherapy alone in patients with HER2+ breast cancer.
ORGANISM(S): Homo sapiens
PROVIDER: GSE50948 | GEO | 2014/01/21
SECONDARY ACCESSION(S): PRJNA219444
REPOSITORIES: GEO
ACCESS DATA